NIKKEI 225
38,405.66 +470.90 (+1.24%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
81.84 -0.79 (-0.96%) GOLD FUTURES
2,306.60 -51.10 (-2.17%) DOW
38,043.43 -342.66 (-0.89%) Bitcoin GBP
50,119.69 -539.11 (-1.06%)
VRTX Oct 2024 260.000 put
| Previous close | 1.5500 |
| Open | 1.3500 |
| Bid | 0.0000 |
| Ask | 4.8000 |
| Strike | 260.00 |
| Expiry date | 2024-10-18 |
| Day's range | 1.3500 - 1.5500 |
| Contract range | N/A |
| Volume | |
| Open interest | 4 |
ZacksVertex (VRTX) to Report Q1 Earnings: What's in the Cards?
Vertex's (VRTX) revenues in the first quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.
ZacksVertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireVertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
LONDON, April 26, 2024--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.
